总时间（秒）：14.39
问答时间（秒）：14.28

```json
[
  {
    "variant_string_id": "EGFR L858R",
    "functional_evidence_aim": "Pathogenic",
    "assessment_steps": [
      {
        "step_name": "Step 1: Define the disease mechanism",
        "extracted_paper_info": "The paper describes that EGFR mutations, including the L858R variant, can lead to constitutive activation of the EGFR signaling pathway, contributing to uncontrolled cell growth and tumor development.",
        "judgment": "Yes",
        "reasoning": "The paper explicitly links EGFR mutations to the disease mechanism of uncontrolled cell growth, which aligns with the known role of EGFR in cancer.",
        "next_step_or_outcome": "Proceed to Step 3"
      },
      {
        "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
        "extracted_paper_info": "The assay used (measuring kinase activity) is an established method for evaluating EGFR activation and its impact on downstream signaling in cancer cells.",
        "judgment": "Yes",
        "reasoning": "Measuring kinase activity is a relevant assay to assess EGFR activation, directly addressing the disease mechanism of unregulated signaling described in Step 1.",
        "next_step_or_outcome": "Proceed to Step 3"
      },
      {
        "step_name": "Step 3a: Basic Controls and Replicates",
        "extracted_paper_info": "The assay included wild-type EGFR as a negative control and a previously characterized loss-of-function EGFR mutant as a positive control.  Experiments were performed in triplicate.",
        "judgment": "Yes",
        "reasoning": "The paper explicitly mentions wild-type and loss-of-function controls, fulfilling the requirements for basic controls. Multiple replicates were also used.",
        "next_step_or_outcome": "Proceed to Step 4"
      },
      {
        "step_name": "Step 3c: Variant Controls",
        "extracted_paper_info": "The paper does not explicitly state the use of other documented pathogenic EGFR variants for comparison with L858R, however, it compares L858R with wild-type.",
        "judgment": "No",
        "reasoning": "While there are controls to indicate normal vs. abnormal, there are not other clearly pathogenic EGFR mutations as a direct control.",
        "next_step_or_outcome": "Proceed to Step 4"
      }
    ],
    "final_evidence_strength": {
      "type": "Pathogenic",
      "strength": "PS3_supporting"
    },
    "overall_conclusion": "The assay demonstrates increased kinase activity with the L858R variant compared to wild-type EGFR, supporting the pathogenicity of the mutation. The lack of other documented pathogenic variants used for control limits the strength to PS3_supporting, but the presence of wild-type controls and replicates still allows it to be considered as an established functional assessment for this variant."
  }
]
```